86884
document
Measurement of health-related quality of life in multiple myeloma . Nordic Myeloma Study Group . When a randomized trial ( NMSG 4/90 ) comparing treatment with melphalan/prednisone to melphalan/ prednisone + interferon alpha-2b in newly diagnosed multiple myeloma was initiated in 1990 , a quality-of-life assessment was integrated into the study . We used the questionnaire ( QLQ-C30 ) developed by the European Organization of Research and Treatment of Cancer ( EORTC ) Study Group on Quality of Life . The QLQ-C30 incorporates five functional scales , three symptom scales , a global health and quality-of life scale and some single symptom measures . The questionnaire was completed prior to treatment and after 1 , 6 , 12 , 24 , 36 and 48 months . 524 ( 90.2 % ) of 581 patients enrolled in the NMSG 4/90 completed the first questionnaire , and 484 ( 83.3 % ) completed all questionnaires given to them . All but one of the scales met the minimum criteria of reliability ( Cronbach 's alpha > / 0.70 ) . Validity was shown by ( 1 ) the ability of the scales to discriminate clearly between patients differing in clinical status as defined by pretreatment W.H.O . performance index and Durie & Salmon stage , and ( 2 ) the sensitivity to changes in objective disease status ( response and relapse ) . This is the first report of the measurement of health-related quality of life in a prospective clinical trial in multiple myeloma . The results demonstrate that the QLQ-C30 is a reliable and valid instrument for the measurement of quality of life in these patients . The data will be used for a cost-utility analysis of the results of the NMSG 4/90 trial .
86885
Intervention_Pharmacological
melphalan/prednisone
86886
Intervention_Pharmacological
melphalan/ prednisone + interferon alpha-2b
86887
Outcome_Physical
health-related quality of life
86888
Outcome_Other
quality-of-life
86889
Outcome_Physical
assessment
86890
Outcome_Physical
Quality of Life
86891
Outcome_Other
quality-of life scale
86892
Outcome_Other
health-related quality of life
86893
Outcome_Other
QLQ-C30
86894
Outcome_Other
quality of life
86895
Participant_Condition
multiple myeloma
86896
Participant_Condition
multiple myeloma
86897
Participant_Sample-size
524
86898
Participant_Sample-size
581
86899
Participant_Sample-size
484